Myasthenia gravis (MG) is an auto-immune disorder of the neuromuscular junction, affecting an estimated range of 36,000 to 60,000 people in the United States per year.1 While the specific pathophysiology is dependent on the subtype of disease, MG ultimately decreases activity of acetylcholine (ACh) at the nicotinic acetylcholine receptors (n-AChR), resulting in impairment of neurotransmitter activity at the neuromuscular junction. Here, CHRNA4 is linked to myasthenia gravis.